Posts Tagged ‘Geron’
by Jeffrey Clark 10 September 2012
Geron has been around for a while… more than 20 years to be exact. The majority of known gardener as the mother of cells of CA North, fighting for the pioneers of the new treatments under the direction of CEO Tom Okarma.
Well, Tom Okarma has disappeared, who resigned in February of last year. And ten months ago new CEO John Scarlett of Geron has decided to completely abandon two decades of research on stem cells to focus on the development of anti-cancer drugs. And now research programs did not get any results. The result can be catastrophic that Geron is now fighting for its existence, as it has for the past two decades with billions of dollars invested in research and testing, but not marketed drugs to show.
FierceBiotech feels strongly about it, which they describe as ‘crisis’ company Geron.
FierceBiotech
Cancel reply
Leave a comment
Name
Geron was a pioneer, leading the development of stem cell research as a public company much sooner than others. Now, this week, the long company believes that the vanguard announced is dismantle its programs for research on stem cells to focus on other products more easily achievable.
Geron has tried to do too much too soon, but the real problem is the cost and time. The development of new therapies in this time requires patience, in the form of an investment of time and capital. And that patience is too thin for those in Geron Conference room.
Some say that it is specific emphasis Geron in treatments of embryonic stem cells that prompted his frustration. Embryonic stem cells are obtained from embryos and have the potential to transform into almost any type of tissue. Adult stem cells are less controversial, but are less flexible. Despite the promise of potentially conditions of healing such as paralysis, the reward for research on stem cells has gone too far. Geron has no product on the market and decided to abandon its program of mother cells after recognizing can make more money by completing two experimental drugs for cancer.
In any case, the overall result is disappointing. Geron, it was the first in the majority of its pipes are focused on stem cell therapies. They were the first to propose a human trial for stem cells. And, then, were the first that the FDA stop such trial. When removes this barrier, it seemed that they can finally break. But, while this clinical trial will continue, it will do so without any definitive development strategy forward. Geron will download their assets of the mother of cells, let go nearly half of its workforce and be relegated to another development hope of oncology company.
What does mean to others by following the footsteps of Geron? You are not sure, but that it may not be good for investors that they were considering support of other companies of stem cells. ? And as the decision of Cordis of j & j to leave the stent market, represents another departure of prestige with a name that was, at the same time, it is a synonym of an entire category of the life sciences industry.
Cancel response
Leave a comment.
Name
Latisse Review and Coupons 